Synthesis, characterization, and in vitro anticancer evaluation of 2-substituted 5-arylsulfonyl-1,3-oxazole-4-carbonitriles
- 41 Downloads
In this series, six new 2-substituted 5-arylsulfonyl-1,3-oxazole-4-carbonitriles were synthesized and characterized by IR, 1H NMR, 13C NMR spectroscopy, elemental analysis and chromato-mass-spectrometry. The anticancer activities of the compounds were evaluated via single high dose (10−5M) against 60 cancer cell lines by the National Cancer Institute according to its own screening protocol. In the next phase, the compounds have been selected for five-dose assay. All synthesized compounds displayed growth inhibitory (GI50) and cytostatic activities (TGI) against the most sensitive cell lines at submicromolar (0.2–0.6 μM) and micromolar concentrations (1–3 μM), respectively. Cytotoxic activity (LC50) of these compounds, with the exception of 4d, against the most sensitive cell lines was also high (5–6 μM). All compounds exhibit high selectivity towards leukemia cell lines, and among them, 4e and 4f showed the best antiproliferative and cytostatic selectivity. Compounds 4c and 4f displayed considerable cytotoxic selectivity towards the renal and breast cancer subpanels. Our results provided evidence for anticancer activities of novel 2-substituted 5-arylsulfonyl-1,3-oxazole-4-carbonitriles which could be useful for developing new anticancer drugs. These substances could also be used as an excellent framework in anticancer research that may lead to discovery of potent antitumor agents.
Keywords2-Substituted 5-arylsulfonyl-1,3-oxazole-4-carbonitriles Synthesis Anticancer activity Selectivity
We would like to thank US Public Health Service and National Cancer Institute, Bethesda, MD, USA, for in vitro evaluation of anticancer activity (providing the NCI-60 cell testing) within the framework of Developmental Therapeutic Program (http://dtp.cancer.gov), and Enamine Ltd for the material and technical support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Joshi S, Bisht AS, Juyal D (2017) Systematic scientific study of 1, 3-oxazole derivatives as a useful lead for pharmaceuticals: a review. Pharma Innov J 6:109–117Google Scholar
- Narang AS, Desai DS (2009) Anticancer drug development. In: Lu Y, Mahato RI (eds) Pharmaceutical perspectives of cancer therapeutics. Springer, New York, NY, p 49–92Google Scholar
- Romagnoli R, Baraldi PG, Prencipe F, Oliva P, Baraldi S, Salvador MK, Lopez-Cara LC, Brancale A, Ferla S, Hamel E, Ronca R, Bortolozzi R, Mariotto E, Porc— E, Basso G, Viola G (2017) Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents Sci Rep 7(1):1–19CrossRefGoogle Scholar
- Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, Mueller T (2010) 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J Med Chem 53:6595–602CrossRefGoogle Scholar
- Semenyuta IV, Kovalishin VV, Kopernik IN, Vasilenko AN, Prokopenko VV, Brovarets VS (2013) Molecular docking of 1,3-oxazole derivatives into the active site of tubulin. Rep Nat Acad Sci Ukr 11:168–173Google Scholar
- Semenyuta IV, Kovalishyn VV, Pilyo SG, Blagodatnyy VN, Trokhimenko EP, Brovarets VS, Metelitsa LA (2014) Application of QSAR models to the search for tubulin inhibitors in a series of derivatives of 1,3-oxazole. Rep Nat Acad Sci Ukr 12:152–157Google Scholar